Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (not Alteryx Therapeutics Ltd as indicated in metadata) covers the month of August 2018. The registrant is an Australian biotechnology company headquartered in Parkville, Victoria. The filing primarily serves to incorporate by reference the company's Corporate Governance Statement for the financial year ended June 30, 2018, as required by ASX Listing Rules 4.7.3 and 4.10.3.
Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. This document is a compliance form regarding corporate governance disclosures rather than a financial results report.
Material Changes
No material financial changes or operational updates are detailed in this specific filing. The document confirms that the Corporate Governance Statement is accurate and up to date as of June 30, 2018, and has been approved by the board.
Guidance, Outlook, and Governance Disclosures
The filing details the company's adherence to the ASX Corporate Governance Council Principles and Recommendations. Key governance disclosures include:
- Board Structure: The company has a Nomination Committee and an Audit Committee, both chaired by independent directors. The board majority consists of independent directors.
- Executive Leadership: The company does not follow the recommendation that the Chair of the Board be an independent director separate from the CEO; an explanation for this deviation is provided in the Corporate Governance Statement.
- Risk Management: The company does not have a dedicated risk committee but employs specific processes to oversee its risk management framework, which is reviewed annually by the board.
- Internal Audit: The company does not have an internal audit function but employs processes to evaluate and improve risk management and internal controls.
- Remuneration: A Remuneration Committee exists, chaired by an independent director. Policies for non-executive and executive remuneration are disclosed separately.
- Diversity: The company has a diversity policy with measurable objectives for gender diversity, disclosed in the Corporate Governance Statement.
Key Facts for Investor Verification
- Verify the full Corporate Governance Statement (pages 47-55 of the Annual Report) for detailed explanations regarding the Chair/CEO structure and risk management processes.
- Confirm the company's financial position and cash runway by reviewing the Annual Report for the year ended June 30, 2018, as this 6-K contains no financial figures.
- Review the company website (http://pranabio.com/investors/) for the full text of the Diversity Policy, Board Skills Matrix, and Committee Charters referenced in this filing.
- Note that the metadata company name "Alteryx Therapeutics Ltd" appears to be incorrect; the filing is for "Prana Biotechnology Limited."